梅曼丁用于治疗精神分裂症初级负面症状:随机对照试验的元分析
Houlin Hong1, Jack Donlon2, Martin Schaefer3,4
1Center for Systems and Community Design, CUNY School of Public Health and Health Policy, New York City, NY, USA.
孟曼丁在治疗精神分裂症的负面症状时表现出显著的疗效,当作为附加疗法使用时. 这种N-甲基-D-酸盐受体对抗剂也改善了患者的认知功能.
科学领域:
- 精神病学和神经科学 精神病学和神经科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 孟曼丁是一种N-甲基-D-酸盐 (NMDA) 受体对抗剂,具有有利的安全性.
- 新出现的证据表明,美曼作为治疗精神分裂症症状的辅助疗法的潜力.
研究的目的:
- 评估孟坦因作为精神分裂症初级负面症状 (PNS) 的补充治疗的疗效.
- 分析孟坦因对精神分裂症患者认知和积极症状的影响.
主要方法:
- 一个系统的元分析,遵循PRISMA指南.
- 在多个数据库 (PubMed,Cochrane,PsycINFO,Embase,China Journal Net) 搜索随机对照试验 (RCT).
- 计算标准化平均差异 (SMD) 和评估偏差风险.
主要成果:
- 与安慰剂相比,孟坦丁显著改善了负面症状 (SMD = 0.79,p = 0.0001).
- 认知功能显示显著改善 (SMD = 0.66,p = 0.0001).
- 没有观察到积极症状的显著改善 (SMD = 0.24,p = 0.1).
结论:
- 这一元分析表明,在治疗精神分裂症的负面症状时,孟坦丁的效果大.
- 虽然在子集分析中没有统计学意义 (N=97),但结果表明有效性,特别是当不作为独立治疗时.
- 未来的研究应该探索NMDAergic药物与其他药物结合用于综合性精神分裂症治疗.
更多相关视频
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
相关概念视频
Alzheimer's Disease: Treatment
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
